Akihiro Takano1, Christer Halldin, Lars Farde. 1. Karolinska Institutet, Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska University Hospital Solna. R5:02, SE-171 76 Stockholm, Sweden. akihiro.takano@ki.se
Abstract
INTRODUCTION: Serotonin and norepinephrine reuptake inhibitors (SNRIs) are antidepressants which have high affinity to both serotonin transporter (SERT) and norepinephrine transporter (NET). In studies in vitro, SNRIs have been reported to show a large variability in the affinity ratio between SERT and NET. For instance, the reported affinity ratio is about 30 for venlafaxine and 1.6 for milnacipran. In this study in nonhuman primates, we aimed to investigate the relationship between SERT and NET affinity by measuring the in vivo occupancy at both transporters of venlafaxine and milnacipran. METHODS: PET measurements with [(11)C]MADAM and [(18)F]FMeNER-D(2) were performed in two female cynomolgus monkeys at baseline and after pretreatment with venlafaxine and milnacipran, respectively. Relationships between dose, plasma concentration, and transporter occupancy were evaluated by saturation analysis using a hyperbolic function. Binding affinity (Kd(plasma)) was expressed by the dose or plasma concentration at which 50 % of the transporter was occupied. RESULTS: SERT and NET occupancy by venlafaxine and milnacipran increased in a dose and plasma concentration-dependent manner. The Kd(plasma) ratio of SERT to NET was 1.9 for venlafaxine and 0.6 for milnacipran. CONCLUSIONS: In this nonhuman primate PET study, the affinity in vivo for SERT and NET, respectively, was shown to be at a similar level for venlafaxine and milnacipran. Both drugs were found to produce balanced inhibition of SERT and NET binding. This observation is not consistent with previous in vitro binding data and illustrates the need to characterize antidepressants at in vivo condition.
INTRODUCTION:Serotonin and norepinephrine reuptake inhibitors (SNRIs) are antidepressants which have high affinity to both serotonin transporter (SERT) and norepinephrine transporter (NET). In studies in vitro, SNRIs have been reported to show a large variability in the affinity ratio between SERT and NET. For instance, the reported affinity ratio is about 30 for venlafaxine and 1.6 for milnacipran. In this study in nonhuman primates, we aimed to investigate the relationship between SERT and NET affinity by measuring the in vivo occupancy at both transporters of venlafaxine and milnacipran. METHODS: PET measurements with [(11)C]MADAM and [(18)F]FMeNER-D(2) were performed in two female cynomolgus monkeys at baseline and after pretreatment with venlafaxine and milnacipran, respectively. Relationships between dose, plasma concentration, and transporter occupancy were evaluated by saturation analysis using a hyperbolic function. Binding affinity (Kd(plasma)) was expressed by the dose or plasma concentration at which 50 % of the transporter was occupied. RESULTS:SERT and NET occupancy by venlafaxine and milnacipran increased in a dose and plasma concentration-dependent manner. The Kd(plasma) ratio of SERT to NET was 1.9 for venlafaxine and 0.6 for milnacipran. CONCLUSIONS: In this nonhuman primate PET study, the affinity in vivo for SERT and NET, respectively, was shown to be at a similar level for venlafaxine and milnacipran. Both drugs were found to produce balanced inhibition of SERT and NET binding. This observation is not consistent with previous in vitro binding data and illustrates the need to characterize antidepressants at in vivo condition.
Authors: Christer Halldin; Johan Lundberg; Judit Sóvágó; Balázs Gulyás; Denis Guilloteau; Johnny Vercouillie; Patrick Emond; Sylvie Chalon; Jari Tarkiainen; Jukka Hiltunen; Lars Farde Journal: Synapse Date: 2005-12-01 Impact factor: 2.562
Authors: Nicholas Seneca; Balázs Gulyás; Andrea Varrone; Magnus Schou; Anu Airaksinen; Johannes Tauscher; Francois Vandenhende; William Kielbasa; Lars Farde; Robert B Innis; Christer Halldin Journal: Psychopharmacology (Berl) Date: 2006-08-04 Impact factor: 4.530
Authors: Darlene C Deecher; Chad E Beyer; Grace Johnston; Jenifer Bray; S Shah; M Abou-Gharbia; Terrance H Andree Journal: J Pharmacol Exp Ther Date: 2006-05-04 Impact factor: 4.030
Authors: Susanne Koch; Susan K Hemrick-Luecke; Linda K Thompson; David C Evans; Penny G Threlkeld; David L Nelson; Kenneth W Perry; Frank P Bymaster Journal: Neuropharmacology Date: 2003-12 Impact factor: 5.250
Authors: Jeffrey H Meyer; Alan A Wilson; Sandra Sagrati; Doug Hussey; Anna Carella; William Z Potter; Nathalie Ginovart; Edgar P Spencer; Andy Cheok; Sylvain Houle Journal: Am J Psychiatry Date: 2004-05 Impact factor: 18.112